GlassScriptPhysician profile
Kuljit S Gill
NPI 1508851254
$1,495.91
in general payments reported to CMS, 2019-2025
33 companies · $289 in 2025
The $289 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $211 · 2021: $331 · 2022: $242 · 2023: $75.47 · 2024: $25.82 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $253.30 | 2019-2023 | |
| Glaukos Corporation | $177.58 | 2025 | Idosetr |
| Alexion Pharmaceuticals, INC. | $135.11 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $109.80 | 2021-2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $72.71 | 2024-2025 | Xdemvy |
| Ge Healthcare | $72.38 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $60.86 | 2022 | |
| Shire North American Group INC | $47.88 | 2019 | |
| Merz Pharmaceuticals, LLC | $47.79 | 2025 | Inbrija, Xeomin |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $44.57 | 2019-2020 | |
| Medtronic USA, INC. | $40.21 | 2019 | |
| Bausch & Lomb Americas INC. | $36.68 | 2022-2023 | Vyzulta |
| Allergan, INC. | $36.06 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $31.68 | 2021 | |
| Jazz Pharmaceuticals INC. | $28.32 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $24.98 | 2019 | |
| Sk Life Science, INC. | $21.46 | 2022 | |
| Collegium Pharmaceutical, INC. | $20.65 | 2022 | |
| Endo Pharmaceuticals INC. | $19.41 | 2019 | |
| Kala Pharmaceuticals, INC. | $18.39 | 2021 | |
| Genentech USA, INC. | $17.79 | 2019 | |
| Avion Pharmaceuticals | $17.49 | 2022 | |
| Eisai INC. | $16.55 | 2022 | |
| Ocular Therapeutix, INC. | $16.42 | 2021 | |
| Zogenix INC. | $15.73 | 2021 | |
| Lilly USA, LLC | $15.43 | 2020 | |
| Tanabe Pharma America, INC. | $15.31 | 2021 | |
| Alcon Vision LLC | $14.93 | 2021 | |
| Kyowa Kirin, INC. | $14.85 | 2019 | |
| Horizon Therapeutics Plc | $14.19 | 2021 | |
| Upsher-Smith Laboratories LLC | $12.99 | 2020 | |
| Vertical Pharmaceuticals, LLC | $12.67 | 2019 | |
| Neurocrine Biosciences, INC. | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kuljit Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.